Clinical Trial SuccessPositive results from the Phase 2 study could validate the potential synergy between bremelanotide and GLP-1 receptor agonists, giving Palatin a foothold in the obesity treatment space.
Market ValuationThe valuation of Palatin's stock appears attractive based on the initial addressable market size, supporting the Buy rating and price target.
Strategic FocusPalatin's strategic focus has shifted primarily to its obesity program, which management views as the primary driver of long-term success.